Abstract
Among protease inhibitors, atazanavir has not been associated with urolithiasis in clinical studies. We describe 11 cases of atazanavir-associated urolithiasis in patients with human immunodeficiency virus (HIV) infection. Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization.
MeSH terms
-
Adult
-
Atazanavir Sulfate
-
Female
-
HIV Infections / complications*
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / adverse effects*
-
HIV Protease Inhibitors / therapeutic use
-
Humans
-
Hydrogen-Ion Concentration
-
Male
-
Middle Aged
-
Oligopeptides / adverse effects*
-
Oligopeptides / therapeutic use
-
Pyridines / adverse effects*
-
Pyridines / therapeutic use
-
Risk Factors
-
Urine / chemistry
-
Urolithiasis / chemically induced*
-
Water / metabolism
Substances
-
HIV Protease Inhibitors
-
Oligopeptides
-
Pyridines
-
Water
-
Atazanavir Sulfate